<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Cancer immunotherapy by CTLA4 blockade" Version="20190501" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">Immune checkpoints are hardwired into the immune system and are crucial for maintaining self-tolerance. Tumors can use these checkpoints to protect themselves from immune system attacks. 
CTLA-4 is expressed on T cells and is a negative regulator of T cell activation. CTLA4 counteracts the activity of the T cell co-stimulatory receptor, CD28, which amplifies TCR signaling once antigen is bound. CTLA-4 and CD28 share the same ligands, CD80 and CD86, although CTLA-4 has a higher affinity. This is represented in the pathway with a blue inhibitory interaction.  One strategy for cancer immunotherapy is to block CTLA-4, thereby removing the negative regulation on T-cell activation. The first checkpoint antibody approved by the FDA was ipilimumab, approved in 2011 for treatment of melanoma. 

The [https://www.nobelprize.org/prizes/medicine/2018/summary/ 2018 Nobel prize in Physiology or Medicine] was awarded to jointly to James Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation.

Partially based on Thermo Fisher [https://www.thermofisher.com/us/en/home/life-science/antibodies/antibodies-learning-center/antibodies-resource-library/cell-signaling-pathways/ctla4-signaling-pathway.html CTLA4 Signaling Pathway] and [https://en.wikipedia.org/wiki/Immune_checkpoint Wikipedia].</Comment>
  <BiopaxRef>f09</BiopaxRef>
  <BiopaxRef>c47</BiopaxRef>
  <Graphics BoardWidth="1256.6289343984486" BoardHeight="807.0032571959587"/>
  <DataNode TextLabel="TCR Signaling" GraphId="a77f8" Type="Pathway">
    <Graphics ShapeType="None" Color="14961e"/>
    </DataNode>
  <DataNode TextLabel="PPP2CA" GraphId="ad3b3" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="Akt Signaling" GraphId="b0708" Type="Pathway">
    <Graphics ShapeType="None" Color="14961e"/>
    </DataNode>
  <DataNode TextLabel="Ipilimumab" GraphId="b24d9" Type="Metabolite" GroupRef="c9cab">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="Tremelimumab" GraphId="ccbcf" Type="Metabolite" GroupRef="c9cab">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="PTPN6" GraphId="d51f3" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="CD80" GraphId="ef383" Type="GeneProduct" GroupRef="c9ea8">
        </DataNode>
  <DataNode TextLabel="CD86" GraphId="c52ec" Type="GeneProduct" GroupRef="c9ea8">
        </DataNode>
  <DataNode TextLabel="Tumor-associated&#10;antigen" GraphId="e1c03" Type="GeneProduct" GroupRef="b966c">
        </DataNode>
  <DataNode TextLabel="MHC II" GraphId="fab43" Type="Protein" GroupRef="b966c">
        </DataNode>
  <DataNode TextLabel="CTLA4" GraphId="fcef8" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="TRA" GraphId="a874d" Type="GeneProduct" GroupRef="f04b6">
        </DataNode>
  <DataNode TextLabel="TRB" GraphId="a1e35" Type="GeneProduct" GroupRef="f04b6">
        </DataNode>
  <DataNode TextLabel="CD28" GraphId="ab01b" Type="GeneProduct" GroupRef="e30ab">
        </DataNode>
  <DataNode TextLabel="PTPN11" GraphId="d4867" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="PIK3CA" GraphId="b5b7a" Type="GeneProduct" GroupRef="e30ab">
    <Comment Source="HomologyMapper">Homology Mapping from Mus musculus to Homo sapiens: Original ID = L:18706</Comment>
        </DataNode>
  <DataNode TextLabel="PIK3R1" GraphId="e4d07" Type="GeneProduct" GroupRef="e30ab">
    <Comment Source="HomologyMapper">Homology Mapping from Mus musculus to Homo sapiens: Original ID = L:18708</Comment>
        </DataNode>
  <DataNode TextLabel="PIK3R2" GraphId="bf650" Type="GeneProduct" GroupRef="e30ab">
    <Comment Source="HomologyMapper">Homology Mapping from Mus musculus to Homo sapiens: Original ID = L:18709</Comment>
        </DataNode>
  <DataNode TextLabel="PIK3CB" GraphId="f85e2" Type="GeneProduct" GroupRef="e30ab">
    <Comment Source="HomologyMapper">Homology Mapping from Mus musculus to Homo sapiens: Original ID = L:74769</Comment>
        </DataNode>
  <DataNode TextLabel="PIK3CD" GraphId="b9d86" Type="GeneProduct" GroupRef="e30ab">
    <Comment Source="HomologyMapper">Homology Mapping from Mus musculus to Homo sapiens: Original ID = L:18707</Comment>
        </DataNode>
  <DataNode TextLabel="PIK3R3" GraphId="ad9e6" Type="GeneProduct" GroupRef="e30ab">
    <Comment Source="HomologyMapper">Homology Mapping from Mus musculus to Homo sapiens: Original ID = L:75669</Comment>
        </DataNode>
  <Interaction>
    <Graphics ConnectorType="Elbow">
      <Point GraphRef="b7b07"/>
      <Point GraphRef="f787c" ArrowHead="mim-conversion"/>
    </Graphics>
    </Interaction>
  <Interaction>
    <Graphics>
      <Point GraphRef="f787c"/>
      <Point GraphRef="a77f8" ArrowHead="mim-conversion"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id1d95f1b3">
    <Graphics>
      <Point GraphRef="e1c03"/>
      <Point GraphRef="f787c" ArrowHead="mim-binding"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id1f573d29">
    <Graphics>
      <Point GraphRef="e02d8"/>
      <Point GraphRef="fcef8" ArrowHead="mim-binding"/>
      <Anchor Position="0.4" Shape="None" GraphId="a92ec"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id459bbff8">
    <BiopaxRef>af6</BiopaxRef>
    <BiopaxRef>daf</BiopaxRef>
    <BiopaxRef>af4</BiopaxRef>
    <Graphics Color="0066ff">
      <Point GraphRef="a92ec"/>
      <Point GraphRef="f1218" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id84dbbf0d">
    <Graphics ConnectorType="Elbow">
      <Point GraphRef="b7b07"/>
      <Point GraphRef="b0708" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idb88160ba">
    <BiopaxRef>b57</BiopaxRef>
    <Graphics>
      <Point GraphRef="a0110"/>
      <Point GraphRef="fcef8" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idc33f25ed">
    <Graphics>
      <Point GraphRef="b7b07"/>
      <Point GraphRef="b0912" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idc73bcd17">
    <BiopaxRef>f7e</BiopaxRef>
    <BiopaxRef>b19</BiopaxRef>
    <Graphics ConnectorType="Elbow">
      <Point GraphRef="ad3b3"/>
      <Point GraphRef="b0708" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="ide8295b07">
    <BiopaxRef>f7e</BiopaxRef>
    <BiopaxRef>b19</BiopaxRef>
    <Graphics ConnectorType="Elbow">
      <Point GraphRef="d4867"/>
      <Point GraphRef="ab01b" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="c7405">
    <Graphics>
      <Point GraphRef="e02d8"/>
      <Point GraphRef="ab01b" ArrowHead="mim-binding"/>
      <Anchor Position="0.41451125618800305" Shape="None" GraphId="f1218"/>
    </Graphics>
    </Interaction>
  <GraphicalLine GraphId="ad323" GroupRef="a09fd">
    <Graphics Color="0066ff">
      <Point/>
      <Point ArrowHead="mim-inhibition"/>
    </Graphics>
  </GraphicalLine>
  <Label TextLabel="IL-2 expression&#10;Immune Response" GraphId="b0912">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="Antagonistic binding" GraphId="d0715" GroupRef="a09fd">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Shape TextLabel="Legend" GraphId="be661" GroupRef="a09fd">
    <Graphics Align="Left" ShapeType="Rectangle"/>
  </Shape>
  <Shape TextLabel="APC" GraphId="d5098">
    <Graphics ShapeType="RoundedRectangle" Color="c0c0c0"/>
  </Shape>
  <Shape TextLabel="T cell" GraphId="f4e64">
    <Graphics ShapeType="RoundedRectangle" Color="c0c0c0"/>
  </Shape>
  <Group GroupId="a09fd" Style="Group"/>
  <Group GroupId="c9cab" GraphId="a0110" Style="Group"/>
  <Group GroupId="e30ab" GraphId="b7b07" Style="Group"/>
  <Group GroupId="c9ea8" GraphId="e02d8" Style="Group"/>
  <Group GroupId="f04b6" GraphId="f787c" Style="Complex"/>
  <Group GroupId="b966c" GraphId="f7f72" Style="Complex"/>
  <InfoBox/>
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c47">
      <bp:ID >8596936</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Enhancement of antitumor immunity by CTLA-4 blockade.</bp:TITLE>
      <bp:SOURCE >Science</bp:SOURCE>
      <bp:YEAR >1996</bp:YEAR>
      <bp:AUTHORS >Leach DR</bp:AUTHORS>
      <bp:AUTHORS >Krummel MF</bp:AUTHORS>
      <bp:AUTHORS >Allison JP</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="af4">
      <bp:ID >16551244</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >A molecular perspective of CTLA-4 function.</bp:TITLE>
      <bp:SOURCE >Annu Rev Immunol</bp:SOURCE>
      <bp:YEAR >2006</bp:YEAR>
      <bp:AUTHORS >Teft WA</bp:AUTHORS>
      <bp:AUTHORS >Kirchhof MG</bp:AUTHORS>
      <bp:AUTHORS >Madrenas J</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b19">
      <bp:ID >21904389</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >New insights into the T cell synapse from single molecule techniques.</bp:TITLE>
      <bp:SOURCE >Nat Rev Immunol</bp:SOURCE>
      <bp:YEAR >2011</bp:YEAR>
      <bp:AUTHORS >Dustin ML</bp:AUTHORS>
      <bp:AUTHORS >Depoil D</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >cancer</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >DOID:162</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Disease</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >T cell</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >CL:0000084</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Cell Type</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f09">
      <bp:ID >30511409</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Immune checkpoint blockade opens a new way to cancer immunotherapy.</bp:TITLE>
      <bp:SOURCE >J Cell Physiol</bp:SOURCE>
      <bp:YEAR >2019</bp:YEAR>
      <bp:AUTHORS >Sadreddini S</bp:AUTHORS>
      <bp:AUTHORS >Baradaran B</bp:AUTHORS>
      <bp:AUTHORS >Aghebati-Maleki A</bp:AUTHORS>
      <bp:AUTHORS >Shanehbandi D</bp:AUTHORS>
      <bp:AUTHORS >Fotouhi A</bp:AUTHORS>
      <bp:AUTHORS >Aghebati-Maleki L</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="af6">
      <bp:ID >22116087</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.</bp:TITLE>
      <bp:SOURCE >Nat Rev Immunol</bp:SOURCE>
      <bp:YEAR >2011</bp:YEAR>
      <bp:AUTHORS >Walker LS</bp:AUTHORS>
      <bp:AUTHORS >Sansom DM</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b57">
      <bp:ID >29339377</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.</bp:TITLE>
      <bp:SOURCE >Cancer Immunol Res</bp:SOURCE>
      <bp:YEAR >2018</bp:YEAR>
      <bp:AUTHORS >Ariyan CE</bp:AUTHORS>
      <bp:AUTHORS >Brady MS</bp:AUTHORS>
      <bp:AUTHORS >Siegelbaum RH</bp:AUTHORS>
      <bp:AUTHORS >Hu J</bp:AUTHORS>
      <bp:AUTHORS >Bello DM</bp:AUTHORS>
      <bp:AUTHORS >Rand J</bp:AUTHORS>
      <bp:AUTHORS >Fisher C</bp:AUTHORS>
      <bp:AUTHORS >Lefkowitz RA</bp:AUTHORS>
      <bp:AUTHORS >Panageas KS</bp:AUTHORS>
      <bp:AUTHORS >Pulitzer M</bp:AUTHORS>
      <bp:AUTHORS >Vignali M</bp:AUTHORS>
      <bp:AUTHORS >Emerson R</bp:AUTHORS>
      <bp:AUTHORS >Tipton C</bp:AUTHORS>
      <bp:AUTHORS >Robins H</bp:AUTHORS>
      <bp:AUTHORS >Merghoub T</bp:AUTHORS>
      <bp:AUTHORS >Yuan J</bp:AUTHORS>
      <bp:AUTHORS >Jungbluth A</bp:AUTHORS>
      <bp:AUTHORS >Blando J</bp:AUTHORS>
      <bp:AUTHORS >Sharma P</bp:AUTHORS>
      <bp:AUTHORS >Rudensky AY</bp:AUTHORS>
      <bp:AUTHORS >Wolchok JD</bp:AUTHORS>
      <bp:AUTHORS >Allison JP</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="daf">
      <bp:ID >1191089</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >The drug surveillance program at the Arizona Medical Center.</bp:TITLE>
      <bp:SOURCE >Ariz Med</bp:SOURCE>
      <bp:YEAR >1975</bp:YEAR>
      <bp:AUTHORS >Trinca C</bp:AUTHORS>
      <bp:AUTHORS >Bressler R</bp:AUTHORS>
      <bp:AUTHORS >Walson P</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >adaptive immune response pathway</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >PW:0000235</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Pathway Ontology</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f7e">
      <bp:ID >19426232</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy.</bp:TITLE>
      <bp:SOURCE >Immunol Rev</bp:SOURCE>
      <bp:YEAR >2009</bp:YEAR>
      <bp:AUTHORS >Podojil JR</bp:AUTHORS>
      <bp:AUTHORS >Miller SD</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >immune response pathway</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >PW:0000023</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Pathway Ontology</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >professional antigen presenting cell</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >CL:0000145</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Cell Type</bp:Ontology>
    </bp:openControlledVocabulary>
  <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"><bp:TERM>cancer pathway</bp:TERM><bp:ID>PW:0000605</bp:ID><bp:Ontology>Pathway Ontology</bp:Ontology></bp:openControlledVocabulary></Biopax>
</Pathway>